StockData
Theriva Biologics, Inc. logo

Theriva Biologics, Inc. (TOVX) stock

TOVXNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 4/30
$0.14+0.00 (0.00%)

Close on Nov 17, 2026Market cap $6.42MP/E –Yield –

Theriva Biologics cash

Cash and short-term investments held at the end of each period.

Theriva Biologics's cash was $11.34M at Jun 30, 2026. For fiscal 2025 it was $13.06M, up 11.5% from the year before. Over ten years it grew -4.6% a year on average. The highest annual figure on record is $67.33M in fiscal 2021.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$13.06M+11.5%
FY2024Dec 31, 2024$11.71M-49.7%
FY2023Dec 31, 2023$23.28M-44.4%
FY2022Dec 31, 2022$41.89M-37.8%
FY2021Dec 31, 2021$67.33M+981.2%
FY2020Dec 31, 2020$6.23M-58.6%
FY2019Dec 31, 2019$15.05M-48.0%
FY2018Dec 31, 2018$28.92M+69.0%
FY2017Dec 31, 2017$17.12M-10.2%
FY2016Dec 31, 2016$19.06M-8.5%
FY2015Dec 31, 2015$20.82M+18.8%
FY2014Dec 31, 2014$17.53M+19.8%
FY2013Dec 31, 2013$14.63M+46.9%
FY2012Dec 31, 2012$9.95M+49.1%
FY2011Dec 31, 2011$6.68M+152.1%
FY2010Dec 31, 2010$2.65M-2.4%
FY2009Dec 31, 2009$2.72M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$11.34M-6.5%
Q1 FY2026Mar 31, 2026$14.43M+44.1%
Q4 FY2025Dec 31, 2025$13.06M+11.5%
Q3 FY2025Sep 30, 2025$7.53M-54.1%
Q2 FY2025Jun 30, 2025$12.12M-27.0%
Q1 FY2025Mar 31, 2025$10.01M-45.2%
Q4 FY2024Dec 31, 2024$11.71M-49.7%
Q3 FY2024Sep 30, 2024$16.41M-47.3%
Q2 FY2024Jun 30, 2024$16.59M-51.6%
Q1 FY2024Mar 31, 2024$18.26M-49.4%
Q4 FY2023Dec 31, 2023$23.28M-44.4%
Q3 FY2023Sep 30, 2023$31.16M-38.3%
Q2 FY2023Jun 30, 2023$34.25M-34.5%
Q1 FY2023Mar 31, 2023$36.08M-36.4%
Q4 FY2022Dec 31, 2022$41.89M-37.8%
Q3 FY2022Sep 30, 2022$50.49M-30.0%
Q2 FY2022Jun 30, 2022$52.27M-29.6%
Q1 FY2022Mar 31, 2022$56.69M-26.3%
Q4 FY2021Dec 31, 2021$67.33M+981.2%
Q3 FY2021Sep 30, 2021$72.14M+1101.2%
Q2 FY2021Jun 30, 2021$74.29M+821.8%
Q1 FY2021Mar 31, 2021$76.89M+662.4%
Q4 FY2020Dec 31, 2020$6.23M-58.6%
Q3 FY2020Sep 30, 2020$6.01M-67.8%
Q2 FY2020Jun 30, 2020$8.06M-62.9%
Q1 FY2020Mar 31, 2020$10.09M-59.2%
Q4 FY2019Dec 31, 2019$15.05M-48.0%
Q3 FY2019Sep 30, 2019$18.65M+95.3%
Q2 FY2019Jun 30, 2019$21.71M+204.6%
Q1 FY2019Mar 31, 2019$24.69M+123.7%
Q4 FY2018Dec 31, 2018$28.92M+69.0%
Q3 FY2018Sep 30, 2018$9.55M-54.6%
Q2 FY2018Jun 30, 2018$7.13M-46.7%
Q1 FY2018Mar 31, 2018$11.04M-18.1%
Q4 FY2017Dec 31, 2017$17.12M-10.2%
Q3 FY2017Sep 30, 2017$21.05M+362.7%
Q2 FY2017Jun 30, 2017$13.38M–
Q1 FY2017Mar 31, 2017$13.47M–
Q4 FY2016Dec 31, 2016$19.06M–
Q3 FY2016Sep 30, 2016$4.55M–

More Theriva Biologics figures

See a number that looks wrong?